ARTA
MYOV

A.R.T. Advisors’s Myovant Sciences Ltd. MYOV Stock Holding History

A.R.T. Advisors’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-29,744
Closed -$155K – 1836
2019
Q3 		$155K Buy
+29,744
New +$221K 0.01% 1217

Other funds holding MYOV

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

A.R.T. Advisors's MYOV Position: Q4 2019 in Review

A.R.T. Advisors sold out of Myovant Sciences Ltd. (MYOV) in Q4 2019, closing a stake of 29,744 shares — an estimated $155K sold.

A.R.T. Advisors first reported a position in MYOV in Q3 2019 and held it in 1 quarter. The position peaked at $155K in Q3 2019. 77 funds tracked by Wall St. Rank hold MYOV as of Q4 2019.

  • A.R.T. Advisors reported no remaining Myovant Sciences Ltd. position as of Q4 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 29,744 Myovant Sciences Ltd. shares in Q4 2019, an estimated $155K.
  • A.R.T. Advisors first reported a position in Myovant Sciences Ltd. in Q3 2019 and held it in 1 quarter.
  • A.R.T. Advisors's Myovant Sciences Ltd. position peaked at $155K in Q3 2019.
  • 77 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.